Expression of tumor-associated antigens in acute myeloid leukemia: Implications for specific immunotherapeutic approaches.
about
Tumor immunotherapy across MHC barriers using allogeneic T-cell precursorsAllogeneic tumor cell vaccines: the promise and limitations in clinical trialsElevated hyaluronan and hyaluronan-mediated motility receptor are associated with biochemical failure in patients with intermediate-grade prostate tumorsFunctional unresponsiveness and replicative senescence of myeloid leukemia antigen-specific CD8+ T cells after allogeneic stem cell transplantation.Leukemia associated antigens: their dual role as biomarkers and immunotherapeutic targets for acute myeloid leukemiaRHAMM (CD168) is overexpressed at the protein level and may constitute an immunogenic antigen in advanced prostate cancer disease.The tumour-associated carbonic anhydrases CA II, CA IX and CA XII in a group of medulloblastomas and supratentorial primitive neuroectodermal tumours: an association of CA IX with poor prognosis.Class II-associated invariant chain peptide down-modulation enhances the immunogenicity of myeloid leukemic blasts resulting in increased CD4+ T-cell responses.What are the endpoints of therapy for acute leukemias? Old definitions and new challenges.High-dose RHAMM-R3 peptide vaccination for patients with acute myeloid leukemia, myelodysplastic syndrome and multiple myeloma.FLT3-regulated antigens as targets for leukemia-reactive cytotoxic T lymphocytes.Increased PRAME-specific CTL killing of acute myeloid leukemia cells by either a novel histone deacetylase inhibitor chidamide alone or combined treatment with decitabine.Activated human gammadelta T cells as stimulators of specific CD8+ T-cell responses to subdominant Epstein Barr virus epitopes: potential for immunotherapy of cancer.Strategies for the identification of T cell-recognized tumor antigens in hematological malignancies for improved graft-versus-tumor responses after allogeneic blood and marrow transplantationApplication of the pMHC Array to Characterise Tumour Antigen Specific T Cell Populations in Leukaemia Patients at Disease Diagnosis.Haematological malignancies: at the forefront of immunotherapeutic innovation.A long road of T-cells to cure cancer: from adoptive immunotherapy with unspecific cellular products to donor lymphocyte infusions and transfer of engineered tumor-specific T-cells.RHAMM/HMMR (CD168) is not an ideal target antigen for immunotherapy of acute myeloid leukemia.Cellular therapy following allogeneic stem-cell transplantation.Translational mini-review series on vaccines: Peptide vaccines for myeloid leukaemias.Graft-versus-host disease after donor leukocyte infusions: presentation and management.Dynamics of cytotoxic T cell subsets during immunotherapy predicts outcome in acute myeloid leukemiaHematopoietic stem cells and progenitors of chronic myeloid leukemia express leukemia-associated antigens: implications for the graft-versus-leukemia effect and peptide vaccine-based immunotherapy.Autologous graft-versus-host disease: harnessing anti-tumor immunity through impaired self-tolerance.Donor leukocyte infusions for the treatment of relapsed acute leukemia after allogeneic stem cell transplantation.Full-intensity and reduced-intensity allogeneic stem cell transplantation in AML.Leukemia-associated antigens as target structures for a specific immunotherapy in chronic myeloid leukemia.Ex vivo characterization of polyclonal memory CD8+ T-cell responses to PRAME-specific peptides in patients with acute lymphoblastic leukemia and acute and chronic myeloid leukemia.Carbonic anhydrase IX: historical and future perspectives.Calreticulin exposure by malignant blasts correlates with robust anticancer immunity and improved clinical outcome in AML patients.Combination of intensive chemotherapy and anticancer vaccines in the treatment of human malignancies: the hematological experienceRecent advances in antigen-loaded dendritic cell-based strategies for treatment of minimal residual disease in acute myeloid leukemia.Immunotherapy of chronic myeloid leukemia: present state and future prospects.Leucine-rich repeat protein PRAME: expression, potential functions and clinical implications for leukaemia.Hyaluronan metabolism in remodeling extracellular matrix: probes for imaging and therapy of breast cancer.Vaccines as consolidation therapy for myeloid leukemia.Peptide vaccine therapy for leukemia.Clinical evaluation of cellular immunotherapy in acute myeloid leukaemia.Clinical peptide vaccination trials for leukemia patients.Novel strategies for immunotherapy in multiple myeloma: previous experience and future directions.
P2860
Q24647124-2D44B2B5-A31F-49BD-8FD1-0EEDA210ADD0Q26852333-0F08ECE8-495D-4968-9855-FEDB2FF77FA0Q28236788-C0EE0D0A-B0D2-4167-A107-6A2C0864C809Q33482103-B25FE16E-CD38-4DBD-BAAA-0592C03445D7Q33491557-0EE5B5E6-0DBC-4FA9-BC58-7B1F903601CFQ33499385-9BCCFEA2-41CA-425A-9717-EBDC4CD41959Q33557891-CDDA1706-BBCA-4A67-9881-F27C70585633Q33707475-D6F159F6-98EF-422E-928D-816D17388831Q33775647-4C9A43C4-F13A-42F7-AAD7-99F817ABC30FQ33952837-DF9611DB-2A62-4C80-BD1A-12CEDA2F56A8Q34350591-4B83C6A4-9E20-4735-8A90-515D90005A03Q34935239-BF43FEF5-4364-4DE3-A2CB-01F93974B5A3Q35222179-B2D2DABA-794A-4165-A694-41F6A838D92BQ35588845-EDDC94CC-A24A-4066-B31C-60C0F3AA3367Q35817394-8FC3E1C2-51B8-4C99-B938-17C7A21CE2C1Q35880618-E2584736-62F2-44BE-8C15-6550072BD3C8Q36062047-6EE18DD7-F7CB-44F0-8C1C-C8175F5F2644Q36366953-A41240D9-3540-458E-88D0-7077F4019BF4Q36612643-D23CA9F5-3C51-48D3-AF48-4F962B14E3BFQ36793112-DC03224D-1646-475F-85C7-CD19D4268335Q36825001-88048E08-5A68-4B89-8D94-A42548AD3BF3Q36946572-FE3B457A-9A2B-4848-AEED-4CEEE187F6CDQ36952252-B0188EF1-0E2C-44C1-968A-C460218723CDQ37008210-69DBE4A7-622C-4D83-9BBB-4B83CE0D8046Q37008223-E9B86569-7E98-41CD-A97C-756419683776Q37061964-B6E68F94-AA85-4BA3-8418-B54E764082DEQ37088532-F99C95E1-FD7A-45CD-8D31-8DC422DEABC8Q37119922-DA40663D-3BC0-4E7D-8BFD-6EB2B41FDF98Q37145154-A07E8E04-482F-49DB-8330-27BD080161A8Q37545824-A579B347-DDEE-4465-9D92-C179B76505B1Q37772085-4E4F9C4E-DC65-4C53-8191-AB1E94D120CCQ37773237-D6F01AC3-F446-4003-A21D-AC57ADCB4E0AQ37773256-8E178617-2D61-48CD-9070-831F1D318BE7Q37783631-2EDA20A7-4479-498F-91E0-CD0A4464D5E8Q37832163-B721152D-071A-4A8B-84A8-CCABC6985957Q37842342-346A936D-62D5-46DF-99F7-BCB66B29D0AFQ37850382-60E80D68-310B-4224-9BB5-C8B9F595BA97Q37868974-9F07F758-D8F1-44B9-B540-7ED0A41E66AEQ37892584-C5220AD6-A034-446E-BBAF-634DB9BA38F1Q38014834-C7E3EA90-77D3-4BD9-966A-EC3E07FBE5DB
P2860
Expression of tumor-associated antigens in acute myeloid leukemia: Implications for specific immunotherapeutic approaches.
description
2006 nî lūn-bûn
@nan
2006 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Expression of tumor-associated ...... immunotherapeutic approaches.
@ast
Expression of tumor-associated ...... immunotherapeutic approaches.
@en
Expression of tumor-associated ...... immunotherapeutic approaches.
@nl
type
label
Expression of tumor-associated ...... immunotherapeutic approaches.
@ast
Expression of tumor-associated ...... immunotherapeutic approaches.
@en
Expression of tumor-associated ...... immunotherapeutic approaches.
@nl
prefLabel
Expression of tumor-associated ...... immunotherapeutic approaches.
@ast
Expression of tumor-associated ...... immunotherapeutic approaches.
@en
Expression of tumor-associated ...... immunotherapeutic approaches.
@nl
P2093
P50
P1433
P1476
Expression of tumor-associated ...... immunotherapeutic approaches.
@en
P2093
Anita Schmitt
Jochen Greiner
Katrin Bosch
Krzysztof Giannopoulos
Lars Bullinger
Michael Schmitt
Richard F Schlenk
P304
P356
10.1182/BLOOD-2006-01-023127
P407
P577
2006-08-24T00:00:00Z